|1.||Decker, Michael W: 2 articles (10/2014 - 09/2010)|
|2.||Bunnelle, William H: 2 articles (09/2010 - 09/2010)|
|3.||Gopalakrishnan, Murali: 2 articles (09/2010 - 09/2010)|
|4.||Anderson, David J: 2 articles (09/2010 - 09/2010)|
|5.||Quik, Maryka: 1 article (10/2014)|
|6.||McGregor, Matthew: 1 article (10/2014)|
|7.||Zhang, Danhui: 1 article (10/2014)|
|8.||Zhang, Jun: 1 article (04/2011)|
|9.||Li, Jianling: 1 article (04/2011)|
|10.||Lenz, Robert A: 1 article (04/2011)|
|1.||Alzheimer Disease (Alzheimer's Disease)
09/01/2010 - "In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease."
04/01/2011 - "ABT-107 is a potent, selective α7 nicotinic receptor agonist under development for treatment of Alzheimer's disease and cognitive deficits associated with schizophrenia. "
|3.||Parkinsonian Disorders (Parkinsonism)
10/01/2014 - "ABT-107 had no effect on Parkinsonism or cognitive performance. "
|4.||Schizophrenia (Dementia Praecox)
09/01/2010 - "Functionally, ABT-107 did not evoke detectible currents in Xenopus oocytes expressing human or nonhuman alpha3beta4, chimeric (alpha6/alpha3)beta4, or 5-HT(3A) receptors, and weak or negligible Ca(2+) responses in human neuroblastoma IMR-32 cells (alpha3* function) and human alpha4beta2 and alpha4beta4 nAChRs expressed in human embryonic kidney 293 cells. "
|1.||Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
|2.||Levodopa (L Dopa)